Value-Based Calculators in Cancer: Current State and Challenges

J Oncol Pract. 2017 Aug;13(8):499-506. doi: 10.1200/JOP.2017.022947. Epub 2017 Jun 15.

Abstract

The ASCO Value Framework, National Comprehensive Cancer Network Evidence Blocks, Memorial Sloan Kettering's DrugAbacus, and Institute for Clinical and Economic Review incremental cost-effectiveness ratio calculator are value-based methodologies that attempt to address the disproportionate increase in cancer care spending. These calculators can be used as an initial step for discussing cost versus value, but they fall short in recognizing the importance of the cancer journey because they do not fully factor the patient's perspective or the global cost of care. This timely review highlights both the limitations and the advantages of each value calculator and suggests opportunities for refinement. Practicing oncologists, payers, and manufacturers should be familiar with value-based calculators because the role these tools play in cost containment is likely to be hotly debated.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / economics*
  • Antineoplastic Agents / therapeutic use
  • Cost-Benefit Analysis / methods*
  • Disease-Free Survival
  • Drug Costs*
  • Humans
  • Neoplasms / drug therapy
  • Neoplasms / economics*
  • Survival Rate

Substances

  • Antineoplastic Agents